The North America HPV Testing and Pap Test Market would witness market growth of 32.6% CAGR during the forecast period (2021-2027).
HPV tests are DNA-based and allow the identification of particular strains of the virus in the specimen. HPV tests if done during the initial screening assist in the identification of abnormal cells that could become cancerous. This could prove beneficial in early detection and consequent prevention of disease, enabling healthcare experts to choose different treatment and/or preventive alternatives.
The growth of the regional market is further fueled by the high affordability, adoption rate, and access to advanced technological products and solutions. In addition to it, the existence of key market players and ongoing strategic initiatives undertaken by them has majorly supplemented the growth of the regional market. For example, Abbott Laboratories; Quest Diagnostics; Becton, Dickinson, and Company; Hologic, Inc. Femasys, Inc.; Arbor Vita Corporation are a few of the leading players operating in the HPV and Pap test market having their headquarters in the U.S.
As per the American Cancer Society, there was 13,170 new cases of invasive cervical cancer were diagnosed and there was a death of around 4,250 women from cervical cancer in the United States in 2019. Therefore, the growing number of cervical cancer cases may surge the demand for HPV Testing and Pap Tests, boosting the market growth. The increasing number of cervical cancer cases has fueled the demand for screening programs. These tests are proved to be beneficial in overcoming the limitations of conventional cervical screening that have resulted in alternative screening paradigms like those including detection of the human papillomavirus. Thus, the growing cases of cervical cancer across the North American region are expected to boost the demand for HPV Testing and Pap Test Market over the forthcoming years.
The US market dominated the North America HPV Testing Market by Country 2020, thereby, achieving a market value of $844.5 million by 2027. The Canada market is experiencing a CAGR of 37.6% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 36.5% during (2021 - 2027).
Based on Type, the market is segmented into Pap Test and HPV Testing. Based on Application, the market is segmented into Cervical Cancer Screening, and Vaginal Cancer Screening. Based on Product, the market is segmented into Consumables, Instruments, and Services. Based on End Use, the market is segmented into Hospitals & Clinics, Laboratories and Other End Users. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global HPV Testing and Pap Test Market is Estimated to Reach USD 7.1 Billion by 2027 at a CAGR of 33.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Hologic, Inc., Quest Diagnostics, Incorporated, Seegene, Inc., Arbor Vita Corporation, Femasys, Inc., and Qiagen N.V.
By Type
By Application
By Product
By End Use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
